Effect of chromium supplementation in treatment of patients with polycystic ovary syndrome candidate for IVF

Clinical trial of the effect of chromium supplementation compared with the placebo on gene expression related to insulin and lipid in women with polycystic ovary syndrome candidate for IVF

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20170513033941N32

Enrollment

Registered

2018-04-05

Start date

2018-02-27

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic ovary syndrome. E28.2

Interventions

Intervention 1: Intervention group: Chromium supplements (Nature Made, California, USA), 200 µg, daily, for 8 weeks orally. Intervention 2: Control group: Placebo (Barij Essence, Kashan, Iran) once a

Eligibility

Sex/Gender

Female

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: Patients with polycystic ovary syndrome Individuals aged 18 to 40 years old

Exclusion criteria

Exclusion criteria: Thyroid dysfunction Diabetes or impaired glucose tolerance

Design outcomes

Primary

Measure	Time frame
Expressed levels of PPAR-? gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.;Expressed levels of GLUT-1 gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.	—

Secondary

Measure	Time frame
Expressed levels of LDLR gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.;Expressed levels of TNF-a gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.;Expressed levels of IL-1 gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.;Expressed levels of IL-8 gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.;Expressed levels of TGF-ß gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.;Expressed levels of VEGF gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.	—

Measure

Time frame

Expressed levels of LDLR gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.;Expressed levels of TNF-a gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.;Expressed levels of IL-1 gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.;Expressed levels of IL-8 gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.;Expressed levels of TGF-ß gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.;Expressed levels of VEGF gene. Timepoint: At the beginning of the study and after 8 weeks of intervention. Method of measurement: PCR.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_z@kaums.ac.ir+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 23, 2026